Prognostic Value of TOP2A Gene Amplification and Chromosome 17 Polysomy in Early Breast Cancer

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2012 Mar 20

PMID 22426810

Citations 12

Authors

Anna Zaczek

Aleksandra Markiewicz

Anna Supernat

Natalia Bednarz-Knoll

Burkhardt Brandt

Barbara Seroczynska

Jaroslaw Skokowski

Jolanta Szade

Piotr Czapiewski

Wojciech Biernat

Marzena Welnicka-Jaskiewicz

Jacek Jassem

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to analyze the occurrence of TOP2A gene amplification and chromosome 17 polysomy in patients with early breast cancer and to correlate the status of these alterations with the prognostic significance expressed as patients' clinical features and survival. Such concurrent analyses of TOP2A gene status and chromosome 17 polysomy have not been performed before. Study group included 149 consecutive stage I-III patients administered standard multimodality treatment. TOP2A abnormalities were examined by standard fluorescence in situ hybridization (FISH) and developed by our group quantitative real-time PCR (qPCR). TOP2A amplification and deletion assessed by FISH were found in 23% and 7% of the tumours, respectively, and by qPCR in 31% and 11% of the tumours, respectively. Chromosome 17 polysomy was detected in 40% of the cases. TOP2A amplification (by qPCR) correlated with shorter disease-free survival (p = 0.03) and overall survival (p = 0.047), and the prognostic value of TOP2A was confirmed in the multivariate analysis (HR = 3.22, 95% CI 1.09-9.56, p = 0.03). TOP2A gene amplification, but not chromosome 17 polysomy, carries negative prognostic information in early breast cancer. Given the aforementioned results, qPCR might serve as a prognostic tool in determining the patient's prognosis.

Citing Articles

A careful reassessment of anthracycline use in curable breast cancer.

Hurvitz S, McAndrew N, Bardia A, Press M, Pegram M, Crown J NPJ Breast Cancer. 2021; 7(1):134.

PMID: 34625570 PMC: 8501074. DOI: 10.1038/s41523-021-00342-5.

HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.

Ahn S, Woo J, Lee K, Park S J Pathol Transl Med. 2019; 54(1):34-44.

PMID: 31693827 PMC: 6986968. DOI: 10.4132/jptm.2019.11.03.

Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.

Ren L, Liu J, Gou K, Xing C J Cancer. 2018; 9(12):2082-2092.

PMID: 29937926 PMC: 6010676. DOI: 10.7150/jca.23681.

Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.

Zhou Z, Liu S, Zhang M, Zhou R, Liu J, Chang Y Dig Dis Sci. 2017; 62(10):2790-2800.

PMID: 28815403 DOI: 10.1007/s10620-017-4718-4.

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Kurozumi S, Padilla M, Kurosumi M, Matsumoto H, Inoue K, Horiguchi J Breast Cancer Res Treat. 2016; 158(1):99-111.

PMID: 27318853 PMC: 4937084. DOI: 10.1007/s10549-016-3856-2.

References

Nielsen K, Ejlertsen B, Moller S, Jorgensen J, Knoop A, Knudsen H . The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D. Acta Oncol. 2008; 47(4):725-34. DOI: 10.1080/02841860801995396. View

Bartlett J, Munro A, Cameron D, Thomas J, Prescott R, Twelves C . Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol. 2008; 26(31):5027-35. DOI: 10.1200/JCO.2007.14.6597. View

Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens M . Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol. 2008; 26(30):4869-74. DOI: 10.1200/JCO.2007.13.4296. View

Tsukamoto F, Miyoshi Y, Egawa C, Kasugai T, Takami S, Inazawa J . Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer. 2001; 93(2):165-70. DOI: 10.1002/cncr.9024. View

Arriola E, Rodriguez-Pinilla S, Lambros M, Jones R, James M, Savage K . Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Breast Cancer Res Treat. 2007; 106(2):181-9. DOI: 10.1007/s10549-006-9492-5. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005; 93(4):387-91. PMC: 2361579. DOI: 10.1038/sj.bjc.6602678. View

Beser A, Tuzlali S, Guzey D, Guler S, Hacihanefioglu S, Dalay N . HER-2, TOP2A and chromosome 17 alterations in breast cancer. Pathol Oncol Res. 2007; 13(3):180-5. DOI: 10.1007/BF02893497. View

Gunn S, Yeh I, Lytvak I, Tirtorahardjo B, Dzidic N, Zadeh S . Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer. 2010; 10:396. PMC: 2915985. DOI: 10.1186/1471-2407-10-396. View

Bednarz N, Eltze E, Semjonow A, Rink M, Andreas A, Mulder L . BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res. 2010; 16(13):3340-8. PMC: 3042432. DOI: 10.1158/1078-0432.CCR-10-0150. View

10.

Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-Galdon M . Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res. 2005; 11(12):4393-9. DOI: 10.1158/1078-0432.CCR-04-2256. View

11.

Bartlett J, Munro A, Dunn J, McConkey C, Jordan S, Twelves C . Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010; 11(3):266-74. DOI: 10.1016/S1470-2045(10)70006-1. View

12.

Knoop A, Knudsen H, Balslev E, Rasmussen B, Overgaard J, Nielsen K . retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:.... J Clin Oncol. 2005; 23(30):7483-90. DOI: 10.1200/JCO.2005.11.007. View

13.

Ichikawa D, Hashimoto N, Hoshima M, Yamaguchi T, Sawai K, Nakamura Y . Analysis of numerical aberrations of specific chromosomes by fluorescent in situ hybridization as a diagnostic tool in breast cancer. Cancer. 1996; 77(10):2064-9. DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2064::AID-CNCR15>3.0.CO;2-T. View

14.

Zaczek A, Markiewicz A, Jaskiewicz J, Pienkowski T, Rhone P, Jassem J . Clinical evaluation of developed PCR-based method with hydrolysis probes for TOP2A copy number evaluation in breast cancer samples. Clin Biochem. 2010; 43(10-11):891-8. DOI: 10.1016/j.clinbiochem.2010.04.060. View

15.

Lehmann U, Glockner S, Kleeberger W, von Wasielewski H, Kreipe H . Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol. 2000; 156(6):1855-64. PMC: 1850085. DOI: 10.1016/S0002-9440(10)65059-6. View

16.

Nakopoulou L, Giannopoulou I, Trafalis D, Gakiopoulou H, Keramopoulos A, Davaris P . Evaluation of numeric alterations of chromosomes 1 and 17 by in situ hybridization in invasive breast carcinoma with clinicopathologic parameters. Appl Immunohistochem Mol Morphol. 2002; 10(1):20-8. DOI: 10.1097/00129039-200203000-00004. View

17.

Downey L, Livingston R, Koehler M, Arbushites M, Williams L, Santiago A . Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res. 2010; 16(4):1281-8. DOI: 10.1158/1078-0432.CCR-09-1643. View

18.

Staaf J, Jonsson G, Ringner M, Vallon-Christersson J, Grabau D, Arason A . High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2010; 12(3):R25. PMC: 2917012. DOI: 10.1186/bcr2568. View

19.

Herrington C, Leek R, Mcgee J . Correlation of numerical chromosome 11 and 17 imbalance with metastasis of primary breast cancer to lymph nodes. J Pathol. 1995; 176(4):353-9. DOI: 10.1002/path.1711760406. View

20.

Salido M, Tusquets I, Corominas J, Suarez M, Espinet B, Corzo C . Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005; 7(2):R267-73. PMC: 1064140. DOI: 10.1186/bcr996. View